Novanta Inc

Novanta Inc (NOVT) Stock Analysis

$128.790

-5.744 (-4.46%)At close

Loading chart…
High
134.490
Open
134.000
VWAP
130.62
Volume
240.65K
Mkt Cap
—
Low
128.570
Amount
31.43M
EV/EBITDA, TTM
21.93

Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others.

AI analysis of Novanta Inc (NOVT)

Sell

Currently, Novanta Inc. (NOVT) is not a good buy. The stock is trading at $128.79, significantly below its analyst price target of $194, but recent performance shows a concerning RSI of 24.523, indicating oversold conditions. Additionally, insider selling has increased by 134.30% over the last month, which raises red flags about management's confidence in the company's near-term prospects. The stock has also seen a 5-day change of -8.84%, suggesting negative momentum. The main risk is the high P/E ratio of 82.54, indicating that the stock may be overvalued compared to its earnings potential.

Analyst Ratings (1)

Buy
1 Buy
0 Hold
0 Sell
Current: 128.79
Low
—
Average
—
High
—

Baird

2026-08-07

Price Target

$194

Outperform

Baird

2026-05-13

Price Target

$173

Outperform

Baird

2026-03-30

Price Target

$144

Outperform

Baird

2026-02-25

Price Target

$150

Neutral

Baird

2025-08-11

Price Target

$133

Neutral

Valuation Metrics

The current forward P/E ratio for Novanta Inc (NOVT) is 8.39, compared to its 5-year average forward P/E of 39.47.

Forward P/E

Strongly Undervalued
5Y Average P/E
39.47
Current P/E
8.39
Overvalued
54.45
Undervalued
24.48

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
26.90
Current EV/EBITDA
21.93
Overvalued
31.28
Undervalued
22.51

Forward P/S

Undervalued
5Y Average P/S
5.44
Current P/S
3.88
Overvalued
6.40
Undervalued
4.48

Alphio AI Price Scenarios for NOVT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NOVT

$155.23

Scenario price

B

Base

Base · 50%NOVT

$145.52

Scenario price

B

Bear

Bear · 25%NOVT

$116.12

Scenario price

Whales holding NOVT

C

CastleArk Management LLC

+ HoldingNOVT

+5.14%

3M Return

S

Southpoint Capital Advisors LP

+ HoldingNOVT

+3.71%

3M Return

C

Champlain Investment Partners, LLC

+ HoldingNOVT

+3.35%

3M Return

B

Baron Capital Group, Inc.

+ HoldingNOVT

+2.54%

3M Return

O

Osterweis Capital Management, Inc.

+ HoldingNOVT

+2.10%

3M Return

F

Fenimore Asset Management, Inc.

+ HoldingNOVT

+1.54%

3M Return

Events Timeline

2026-08-05 (ET)

17:00:00

Novanta Reports Q2 Revenue of $265.8 Million

17:00:00

Sees FY26 Revenue of $1.13B-$1.14B

17:00:00

Sees Q3 Revenue of $300M-$304M

2026-07-27 (ET)

08:30:00

Novanta Completes Acquisition of Riverpoint Medical

2026-06-29 (ET)

17:30:00

Selling Stockholders Plan to Sell 2.14M Common Shares

News

NOVT FAQ — answered by Alphio AI

Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others. It operates in the Technology sector (MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SU industry).

Currently, Novanta Inc. (NOVT) is not a good buy. The stock is trading at $128.79, significantly below its analyst price target of $194, but recent performance shows a concerning RSI of 24.523, indicating oversold conditions. Additionally, insider selling has increased by 134.30% over the last month, which raises red flags about management's confidence in the company's near-term prospects. The stock has also seen a 5-day change of -8.84%, suggesting negative momentum. The main risk is the high P/E ratio of 82.54, indicating that the stock may be overvalued compared to its earnings potential.

1 analysts cover NOVT: 1 rate it Buy, 0 Hold and 0 Sell.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading